Idera Pharmaceuticals acquires rare orphan disease company Aceragen
Idera Pharmaceuticals, a US-based biopharma company, has acquired Aceragen, a biotechnology company focused on developing drugs for rare, orphan pulmonary, and rheumatic diseases. The acquisition was carried out through an all-stock deal in a ratio under which original Idera Pharmaceuticals’ shareholders will own a stake of around 33% in the combined company, while Aceragen’s shareholders […]